Nature Communications (Jul 2020)
Long-lasting severe immune dysfunction in Ebola virus disease survivors
- Aurélie Wiedemann,
- Emile Foucat,
- Hakim Hocini,
- Cécile Lefebvre,
- Boris P. Hejblum,
- Mélany Durand,
- Miriam Krüger,
- Alpha Kabinet Keita,
- Ahidjo Ayouba,
- Stéphane Mély,
- José-Carlos Fernandez,
- Abdoulaye Touré,
- Slim Fourati,
- Claire Lévy-Marchal,
- Hervé Raoul,
- Eric Delaporte,
- Lamine Koivogui,
- Rodolphe Thiébaut,
- Christine Lacabaratz,
- Yves Lévy,
- PostEboGui Study Group
Affiliations
- Aurélie Wiedemann
- INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil
- Emile Foucat
- INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil
- Hakim Hocini
- INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil
- Cécile Lefebvre
- INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil
- Boris P. Hejblum
- Department of Public Health, Inserm Bordeaux Population Health Research Centre, Univ. Bordeaux, Inria SISTM, UMR 1219, Vaccine Research Institute (VRI)
- Mélany Durand
- Department of Public Health, Inserm Bordeaux Population Health Research Centre, Univ. Bordeaux, Inria SISTM, UMR 1219, Vaccine Research Institute (VRI)
- Miriam Krüger
- Department of Public Health, Inserm Bordeaux Population Health Research Centre, Univ. Bordeaux, Inria SISTM, UMR 1219, Vaccine Research Institute (VRI)
- Alpha Kabinet Keita
- TransVIHMI, IRD UMI 233, INSERM U1175, Montpellier University
- Ahidjo Ayouba
- TransVIHMI, IRD UMI 233, INSERM U1175, Montpellier University
- Stéphane Mély
- Laboratoire P4 Inserm-Jean Mérieux, US003 INSERM
- José-Carlos Fernandez
- INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil
- Abdoulaye Touré
- TransVIHMI, IRD UMI 233, INSERM U1175, Montpellier University
- Slim Fourati
- Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, Laboratoire de Virologie
- Claire Lévy-Marchal
- Pôle de Recherche Clinique (PRC), INSERM
- Hervé Raoul
- Laboratoire P4 Inserm-Jean Mérieux, US003 INSERM
- Eric Delaporte
- TransVIHMI, IRD UMI 233, INSERM U1175, Montpellier University
- Lamine Koivogui
- Institut National de Santé Publique (INSP)
- Rodolphe Thiébaut
- Department of Public Health, Inserm Bordeaux Population Health Research Centre, Univ. Bordeaux, Inria SISTM, UMR 1219, Vaccine Research Institute (VRI)
- Christine Lacabaratz
- INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil
- Yves Lévy
- INSERM U955 Team 16, Vaccine Research Institute, Faculté de Médecine, Université Paris-Est Créteil
- PostEboGui Study Group
- DOI
- https://doi.org/10.1038/s41467-020-17489-7
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 11
Abstract
Patients who have recovered from Ebola virus can have ongoing health problems. Here, the authors show that 35 Guinean survivors of the last West African Ebola epidemic have a chronic disease with high inflammatory cytokine expression and other markers of immune activation as well as evidence of intestinal tissue damage nearly two years after their release from hospital.
